American Society of Ketamine Physicians, Psychotherapists & Practitioners - 2021 Annual Conference

Tuesday, 2 November 2021 4:00 PM - Saturday, 6 November 2021 4:30 PM PDT

This event is currently not on sale. Please contact the organizer at the email address on the bottom right corner.

Registration

Access code applied successfully. Remove

Invalid access code. Try again
Have an access code?

Sale ended

Thursday Morning Introductory Ketamine Lectures - Limited Space Partial Approval - $250.00

This ticket entitles the purchaser entry into the introductory lectures on Thursday morning only. Conference tickets still need to be purchased to attend the ASKP3 Fourth Annual Conference. No Discounts are available for Introductory Ketamine Lecture tickets.

sales ended

VIRTUAL ONLY - American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Conference Partial Approval - $650.00

This ticket gives virtual access to the conference only.

Enter your discount code

Subtotal (excluding fees and discounts)
Fee
Total amount

Event Information

Tuesday, 2 November 2021 4:00 PM - Saturday, 6 November 2021 4:30 PM PDT

This is the fourth annual conference for the American Society of Ketamine Physicians, Psychotherapists & Practitioners. A conference involving multi-disciplinary speakers discussing ketamine use for mood disorders, psychotherapy and pain conditions. Please join us for this educational conference and extraordinary networking experience.

This conference is sure to sell out so be sure to register soon!

AMERICAN SOCIETY OF KETAMINE PHYSICIANS, PSYCHOTHERAPISTS & PRACTITIONERS

4TH ANNUAL MEETING

NOVEMBER 2ND-6TH

AGENDA

Tuesday, November 2^nd

Block 1: 4:00-5:00 PST/7:00-8:00 EST

Room 1: Building a Therapeutic Toolbox: Applying Dialectical Behavioral Therapy Strategies to Ketamine Assisted Psychotherapy – Cindy McKinzie, PsyD & Rena Beyer, LCSW

Room 2: Patient Preparation: How Providers Can Create the Best Patient Experience – Megan Oxley, MD & Kathleen Barrett, PhD

Room 3: Ketamine and TMS: How to Combine Two Powerful Neuromodulator Therapies - Erin Amato, MD & Rocky Sullivan, DO

Block 2: 5:00-6:00 PST/8:00-9:00 EST

Room 1: Building a Therapeutic Toolbox: Applying Dialectical Behavioral Therapy Strategies to Ketamine Assisted Psychotherapy – Cindy McKinzie, PsyD & Rena Beyer, LCSW

Room 2: Patient Preparation: How Providers Can Create the Best Patient Experience – Megan Oxley, MD & Kathleen Barrett, PhD

Room 3: Ketamine and TMS: How to Combine Two Powerful Neuromodulator Therapies - Erin Amato, MD & Rocky Sullivan, DO

Wednesday, November 3^rd

Block 1: 4:00-5:00 PST/7:00-8:00 EST

Room 1: Esketamine: Incorporating Esketamine Into an Existing Ketamine Practice and Troubleshooting the Challenges - Erin Amato, MD & Sandhya Prashad, MD

Room 2: Insurance Issues in a Ketamine Practice: Challenges With Insurance in the Ketamine Space and How to Manage Them - Lisa Harding, MD

Room 3: Legal Considerations: An Opportunity to Discuss Legal Considerations With Lawyers Well Educated in Ketamine Space - Daniel Sternthal, Esq & Stuart Miller, Esq

Block 2: 5:00-6:00 PST/8:00-9:00 EST

Room 1: Esketamine: Incorporating Esketamine Into an Existing Ketamine Practice and Troubleshooting the Challenges - Erin Amato, MD & Sandhya Prashad, MD

Room 2: Insurance Issues in a Ketamine Practice: Challenges With Insurance in the Ketamine Space and How to Manage Them - Lisa Harding, MD

Room 3: Legal Considerations: An Opportunity to Discuss Legal Considerations With Lawyers Well Educated in Ketamine Space - Daniel Sternthal, Esq & Stuart Miller, Esq

Friday, November 5th

8:00a–8:30a PST - State of the ASKP3 Union

Welcome, Recap of 2021 – Sandhya Prashad, MD, President of ASKP3
Standards & Ethics Presentation – Sandhya Prashad, MD & Rocky Sullivan, DO

8:30a–10:30a PST - Speaker Block 1

Nicholas Mischel, MD, PhD – Psycho-Physiologic Outcomes of Ketamine Treatment for Depression in Clinical Settings: Behavioral and Physiologic Predictors of Response
Philip Getson, MD – Ketamine Infusions for the Treatment of Complex Regional Pain Syndrome
Lisa Harding, MD – Esketamine

Q&A Hosts – Rocky Sullivan, DO

10:30a–11:30a PST - Lunch – Sponsor Opportunities

11:30a–1:30p PST - Speaker Block 2

Jenny B. Dwyer, MD, PhD – Ketamine for Pediatric Treatment Resistant Depression: Advances, Challenges, and Unanswered Questions
Jason Sienknecht, LPC, CAC II – The Varieties of Ketamine-Induced Non-Ordinary States of Consciousness in Ketamine-Assisted Psychotherapy
Elizabeth Wassenaar, MD – The Use of Ketamine in Patients with Eating Disorders

Q&A Host - Nykol Bailey, PMHNP, CRNA

1:30p–2:30p PST - Break – Sponsor Opportunities

2:30p–4:30p PST - Speaker Block 3

Brittany O’Brien, PhD – Differential Responses to Ketamine and the Role of Childhood Maltreatment
Pamela Kryskow, MD – Roots to Thrive Ketamine Assisted Therapy: Group Therapy in a Resiliency Model
Sandhya Prashad, MD, Rocky Sullivan, MD & Lisa Harding, MD – Panel Discussion

Q&A Hosts – Erin Amato, MD & Rena Beyer, LCSW

Saturday, November 6th

8:00A–10:00A PST - Abstract Presentations

Rachel Landrum, MA – Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients
Florian Birkmayer, MD – Olfactory Stimulation to Enhance Ketamine Therapy: A Review of the Evidence for Synergy and Case Reports

Q&A Hosts - Rocky Sullivan, DO & Kathleen Barrett, PhD

Martha Koo, MD – IV Ketamine Outcomes for TMS Therapy Non-Remitters: A Case Series
Tiago Gil, MD – The Use Of S-Ketamine in Alzheimer's Dementia: A Case Report

Q&A Hosts - Rocky Sullivan, DO & Kathleen Barrett, PhD

10:00A–10:30A PST – Break - sponsor opportunities

10:30A–12:30P PST - Speaker Block 1

Daniel Sternthal, Esq & Stuart Miller, Esq – Legal Issues in the Ketamine Space
Roger S. McIntyre, MD, FRCPC – The International Guidelines for Ketamine/Esketamine in Adults with Treatment-Resistant Depression: What is the Consensus?
Roger S. McIntyre, MD, FRCPC – The Efficacy of Ketamine in Adults with Treatment-Resistant Bipolar Depression

Q&A Hosts - Cindy Van Praag, MD & Megan Oxley, MD

12:30P–1:30P PST – Lunch – Sponsor Opportunities

1:30P–3:30P PST – Speaker Block 2

John Berner, MD – Macrosomia Analysis May Identify Optimal Treatment With Ketamine and Rapamycin Combination Therapy
Joshua Siegel, MD – Prolonged Ketamine Infusion Modulates Limbic Connectivity and Induces Sustained Remission of Treatment-Resistant Depression
Veronika Gold, LMFT – Becoming a Ketamine-Assisted Psychotherapist

Q&A Host - Sandhya Prashad, MD

In the event that ASKP3 is unable to conduct an in-person conference due to circumstances beyond their control, ASKP3 intends to conduct its conference virtually. Attendees that purchased an in-person ticket will be refunded the difference. Full refunds will not be provided.

Speakers

Learn more aboutRoger S. McIntyre, MD

Roger S. McIntyre, MD

Professor of Psychiatry and Pharmacology, University of Toronto, Canada Head, Mood Disorders Psychopharmacology Unit http://www.mdpu.ca/ Chairman and Executive Director, Brain and Cognition Discovery

University of Toronto

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE) and is the CEO of Braxia Scientific. Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 700 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders. Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level. Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Learn more aboutVeronika Gold, LMFT

Veronika Gold, LMFT

CO-FOUNDER AND PSYCHEDELIC PSYCHOTHERAPIST

Polaris Insight Center

Veronika is a marriage and family therapist who specializes in the treatment of trauma. She is a Certified Somatic Experiencing Practitioner, Certified EMDR therapist, Consultant, and Facilitator, and Realization Process Teacher. She has undergone multiple trainings in psychedelic-assisted psychotherapy, including advanced training through the Ketamine Training Center and Kriya Institute, and MDMA-Assisted Therapy Training through MAPS, and is currently a Sub-Investigator and Co-therapist, a supervisor and a trainer on the MAPS MDMA-Assisted Therapy Clinical Trials for the treatment-resistant PTSD. She regularly presents at conferences and teaches on trauma and psychedelic-assisted therapies. Veronika is a lead trainer in the Polaris Insight Training Program.

Learn more aboutBrittany O'Brien

Brittany O'Brien

Clinical Psychologist, Assistant Professor at Baylor College of Medicine

Baylor College

Dr. O’Brien is a licensed clinical psychologist and assistant professor at Baylor College of Medicine. She received her doctoral degree from the New School for Social Research in New York City and completed her post-doctoral fellowship at Baylor College of Medicine. She is a co-investigator on several federal, foundation, and industry sponsored trials investigating novel treatments for patients with treatment-resistant mood, anxiety and trauma-related disorders. Her clinical work specializes in treatment of patients with chronic mood disorders and supervising trainees interested in working with this population. She has a particular interest in ketamine as a treatment for patients with treatment resistant depression and furthering the field's understanding of factors that may enhance and limit treatment response.

Learn more aboutDaniel Sternthal

Daniel Sternthal

Attorney

Munsch Hardt

Daniel Sternthal is a recognized authority on regulatory, business, and policy issues related to health care. He serves as strategic counsel to a diverse range of health care entities (both for profit and not-for-profit) as they evaluate regulatory, administrative and transactional opportunities and navigate through challenges. For the last 20 years Daniel has focused his practice on the health care industry, representing providers across the continuum of care including individual and group medical practices, hospitals, long-term care facilities and an array of ancillary service providers on issues relating to regulatory, operational and corporate matters. Daniel is Board Certified in Health Law by the Texas Board of Legal Specialization, a certification held by fewer than 80 attorneys statewide. He is an active member of the national, state and local health care bar, currently serving as Chair of the American Health Law Association’s Post-Acute & Long Term Service Practice Group and a member of the State Bar of Texas’ Health Law Section. Daniel has previously served as a member of the LeadingAge Legal Committee and as an officer of the Houston Bar Association’s Health Law Section. He also served as an adjunct professor at the University of Houston-Clear Lake where he taught a course on the Legal Aspects of Healthcare Administration and held a position as an adjunct professor for the Spring 2016 semester at the University of Houston, teaching a course on Long Term Care and the Law. Daniel earned his JD from The University of Texas School of Law. He holds a master’s degree from The Hebrew University of Jerusalem and a bachelor’s degree from McGill University.

Learn more aboutJennifer B. Dwyer, MD

Jennifer B. Dwyer, MD

Assistant Professor; Co-Director and Co-Founder of the Pediatric Depression Clinic, Child Study Center

Yale School of Medicine

Dr. Dwyer completed her MD and PhD (Pharmacology) at the Univ. of California, Irvine, where she studied the development of the dopamine system in adolescence. She works clinically with children and adults, with a broad interest in how the brain and mind develop over time. She studies treatment-refractory adolescent depression, and hopes to better predict who will respond to different types of treatments, ranging from intensive psychotherapies to novel pharmacotherapeutics (e.g. ketamine).

Learn more aboutElizabeth Wassenaar, MD

Elizabeth Wassenaar, MD

Regional Medical Director

Pathlight Mood & Anxiety Center

Dr. Elizabeth Wassenaar comes to Pathlight following her role as Medical Director at Eating Recovery Center (ERC), Denver. Prior to joining ERC, Dr. Wassenaar served as a staff psychiatrist and medical director at the Lindner Center of Hope with emphasis on Child and Adolescent outpatient medication management and therapy. She is Board Certified in Psychiatry and Neurology, Child and Adolescent Psychiatry and Obesity Medicine. Dr. Wassenaar has completed advanced training in: Child and Adolescent Psychotherapy Program, Cincinnati Psychoanalytic Institute Family Based Therapy (FBT) Training, University of California San Diego Eating Disorders Treatment and Research Center Motivational Interviewing for Obesity in the Primary Care Setting, DuPont/Nemours Children’s Hospital System Dr. Wassenaar is a Clinical Instructor at University of Colorado Anschutz Medical Campus and served as Assistant Professor at the University of Cincinnati Department of Psychiatry and Adjunct Assistant Professor Cincinnati Children’s Hospital Medical Center prior to relocating to Denver. In addition to her clinical practice she is an avid researcher and academic writer in the area of eating disorders.

Learn more aboutJason Sienknecht, LPC, CACII

Jason Sienknecht, LPC, CACII

Psychedelic Psychotherapist

PRATI & The Wholeness Center

Jason Sienknecht, LPC, CAC II, is a psychedelic psychotherapist with an interest in the potential for expanded states of consciousness to bring about healing and wholeness. He is a trained ketamine-assisted therapist and currently uses oral and intramuscular ketamine to help people heal from treatment-resistant depression and PTSD. He is also a MAPS-trained MDMA-assisted psychotherapist.

Learn more aboutJoshua Siegel, MD

Joshua Siegel, MD

Psychiatrist

Washington University Saint Louis

My professional area of interest is in developing and understanding novel fast-acting psychopharmacological agents to treat psychiatric illness. I am currently involved in neuroimaging studies of ketamine, psilocybin, allopregnanolone and similar molecules. This is the convergence of my interests in systems neuroscience, neurotransmitters, synaptic plasticity, psychiatry and consciousness. The only thing that excites me as much as the prospect of being a part of the accelerating field of neuroscience is the prospect that I might get to use some of these advances to change the life of a human being.

Learn more aboutNicholas Mischel, MD

Nicholas Mischel, MD

Assistant Professor, Director of Interventional Psychiatry and Neuromodulation Research

Wayne University School of Medicine, Department of Psychiatry and Behavioral Neurosciences

In addition to a background in integrative neurophysiology research from MD/Ph.D. training at Wayne State University, I completed my psychiatry residency at Duke University Medical Center, focusing on brain stimulation clinical/translational research. I joined the Department of Psychiatry and Behavioral Neurosciences at Wayne State University's School of Medicine in 2019 and have experience in treatment of medication-resistant mood disorders, including clinical brain stimulation with repetitive transcranial magnetic stimulation (rTMS), and intravenous ketamine infusions. I currently direct the Interventional Psychiatry and Neuromodulation Research Program in the Department of Psychiatry and Behavioral Neurosciences at Wayne State University School of Medicine and treat patients with medication resistant mood disorders. Our research is focused on developing “physiometrics”, psycho-physiologic biomarkers that inform real-world psychiatric practice.

Learn more aboutPamela Kryskow, MD

Pamela Kryskow, MD

Ketamine-Assisted Therapy, MD, EFT, Trainer

Roots To Thrive

Dr. Pamela Kryskow comes to the RTT-KAT team with a wealth of experience in conventional medicine augmented by her knowledge and research of psychedelic-assisted therapies and microdosing, placing her at the forefront of this new, rapidly emerging paradigm. She works as a clinical instructor in the Department of Medicine at the University of British Columbia. Specializing in alleviating the complex modality of pain, she successfully synthesizes her training in family, rural, emergency, pain, counselling and functional medicine.

Learn more aboutPhilip Getson, DO

Philip Getson, DO

Family Physican

Philip Getson

Philip Getson, D.O. is a family physician in practice since 1976 in New Jersey. He is a locally, nationally and internationally recognized expert in the diagnosis and treatment of Reflex Sympathetic Dystrophy/Complex Regional Pain Syndrome and has lectured extensively on the subject. He was an Assistant Professor of Medicine in Neurology at Drexel University Hospital in Philadelphia until its closing. Additionally, he completed training for qualification as a Certified Cancer Support Educator from the Center for Advancement in Cancer Education. He is a Board Certified Thermologist and has reviewed more than 15,000 Thermographic Studies of the breast, thyroid and neuromuscular system. He has been certified by four Thermographic Boards and has lectured internationally regarding Thermographic Testing, and has authored several papers on the subject. He has served as Vice President of the American Academy of Thermology. Dr. Getson is also chairman of the committee that has formulated the national protocols for breast thermography that have been accepted by the International Thermographic Community.

Ticket	Price	Quantity
		1

Finalizing your payment

Other events by this organizerMore by

Events you might like

Registration Access code applied successfully. Remove Invalid access code. Try again Have an access code?

Thursday Morning Introductory Ketamine Lectures - Limited Space Partial Approval - $250.00

VIRTUAL ONLY - American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Conference Partial Approval - $650.00

Enter your discount code

1. Select Seats

2. Review and Proceed

Event Information

Friday, November 5th

Saturday, November 6th

Event Location

About Organizer